Like most payers, Medicaid programs struggle with the cost of drugs. A report from Magellan Health gives some trends and data on prescription medication use in the Medicaid sector. (Magellan Report) The report covers 2018 and is based on Magellan’s customers’ experience. As always when looking at medication spending trends, it is important to try to disentangle the effects of utilization and prices, and to focus on net spending after rebates and discounts. The federal government mandates very significant discounts for the Medicaid programs and states may have their own additional rebate arrangements. It is useful to look at the last three years. In 2016, total net trend was a 1.9% increase, but while traditional drug, branded and generic, spending declined, that on specialty drugs rose 20.5%. In 2017, the total rise was actually a decline of 4.4%, with traditional spending going down 9.7% while specialty rose 4.6%. And in 2018, the total increase in spending was .8%, traditional declined 2.6% and specialty rose 6.1%. The gross or pre-discount cost in 2017 was $108.88 per claim while the net or after discount cost was $45.66, which shows the size of Medicaid rebates. In 2018 the numbers were $113.32 gross cost per claim and $46.03 net. Out of the .8% rise in net spending in 2018, traditional drug price contributed a seventy-one cent decline, while traditional utilization was responsible for a 5.2% decline, which is a little surprising. On the specialty side, there was a $77 increase in prices but a 5.5% decline in utilization. To give you a better sense of just how impactful specialty drugs are, they represent only 1.5% of all claims, but account for 43% of net spending. Magellan is projecting that net Medicaid spending will continue to increase more rapidly in the next three years, but still be very modest at around 2% a year, all driven by specialty drug pricing. The top therapeutic categories for Medicaid spending are HIV, anti-psychotics and hemophilia. Some of the approaches, in addition to the usual discounts and rebates, that states are trying in their efforts to control spending include outcomes-based contracting and subscription approaches.
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
This is an outstanding report on total global drug spending and trends, with projections out to 2025. It helps you understand this important area of health care, which does much...
June 1, 2021
MedPAC 2019 Report to Congress
June 18, 2019
Best Buy is another large corporation trying to make a bet on health care, in this case largely by providing remote patient monitoring services. The company made yet another significant...
October 13, 2021
Just so men don’t feel left out, a company called Numan has raised $40 million for an app, yada, yada, yada, helping men with ED and other health issues. Also...
October 11, 2021
Money streams in to Flo, which sells an app for women to track menstrual cycles, etc. Investors hope they won’t be left up a creek. $100 million in financing that...
October 11, 2021
Access ACO Care Management Chronic Disease Comparative Effectiveness Consumer Directed Health Consumers Devices Disease Management Drugs EHRs Elder Care End-of-Life Care FDA Financings Genomics Government Health Care Costs Health Care Quality Health Care Reform Health Insurance Health Insurance Exchange HIT HomeCare Hospital Hospital Readmissions Legislation M&A Malpractice Meaningful Use Medicaid Medical Care Medicare Medicare Advantage Mobile Pay For Performance Pharmaceutical Physicians Providers Regulation Repealing Reform Telehealth Telemedicine Wellness and Prevention Workplace